Strengthening Relationships with Pharmaceutical Companies

「In the pharmaceutical manufacturing and marketing business, sales from co-promotion with major partner pharmaceutical companies remained strong. The company will continue promoting sales of its own products while preparing to update its manufacturing execution system, which visualizes manufacturing processes and provides instructions and support to workers.」

「In September 2021, the company also launched the Industry-Academia Collaborative IBD Project—Initiatives for IBD Aimed at Improving Quality of Life—for young physicians involved in treating inflammatory bowel disease (IBD) and pharmaceutical companies handling IBD treatments. The project provides a forum for discussion that transcends the boundaries between companies and between companies and the medical community, with the aim of providing patients with the best possible treatment.」

「In the pharmaceutical manufacturing and marketing business, sales from co-promotion with major partner pharmaceutical companies have remained strong.」

「In the core CSO business, the group is focusing on developing highly capable personnel sought by healthcare providers by expanding training programs for MRs specializing in specific therapeutic areas and improving quality through ongoing education, while also seeking to expand its scale through M&A.」

「In the CSO business, the group is focusing on enhancing expertise and added value by operating an in-house certification system, providing training by therapeutic area, and offering e-learning. Going forward, it will continue to propose initiatives suited to the era of living with COVID-19, leveraging its highly specialized CMRs and sales capabilities with pharmaceutical companies.」

「In the CSO business, demand from pharmaceutical manufacturers for CMRs (contract MRs) is increasing. The group is also focusing on enhancing expertise, which has raised the per-person staffing rate. Going forward, it will continue to propose initiatives suited to the era of living with COVID-19, leveraging its highly specialized CMRs and sales capabilities with pharmaceutical companies.」

「The external environment for the group’s core CSO business is characterized by growing demand from pharmaceutical manufacturers for CMRs (contract MRs). Against this backdrop, the group has maintained the industry’s highest number of contracts through its ongoing efforts to train highly specialized CMRs and actively market to pharmaceutical companies. CMR orders are also increasing, and the group is working to strengthen recruitment.」

「In the CSO business, the core of Apoplus Station Co., Ltd., the group has maintained the industry’s highest number of contracts through its ongoing efforts to train highly specialized MRs and actively market to pharmaceutical companies. Orders for MRs are also increasing, and the group is working to strengthen recruitment.」

「Through its ongoing efforts to train highly specialized MRs and actively market to pharmaceutical companies, the group has maintained the industry’s highest number of contracts while increasing the number of MR contracts.」

「The group is also working to train highly specialized MRs and strengthen sales efforts directed at pharmaceutical companies, while the number of dispatched MRs is progressing as planned.」

「The group is also working to train highly specialized MRs and strengthen sales efforts directed at pharmaceutical companies to develop new customers and extend contracts for existing engagements.」

「Amid a downward trend in the MR staffing market, the group continues to maintain the industry’s highest number of contracts. It is also working to train highly specialized MRs and strengthen sales efforts directed at pharmaceutical companies to develop new customers and extend contracts for existing engagements.」

「Orders for MR staffing are progressing as planned, and the number of contracts with pharmaceutical companies remains the highest in the industry. The group is also training highly specialized MRs and strengthening sales efforts directed at pharmaceutical companies to develop new customers and extend contracts for existing engagements.」

「The number of contracts with pharmaceutical companies remains the highest in the industry. The group is also training highly specialized MRs and strengthening sales efforts directed at pharmaceutical companies to develop new customers and extend contracts for existing engagements.」

「The number of contracts with pharmaceutical companies remains the highest in the industry. The group is also training highly specialized MRs and strengthening sales efforts directed at pharmaceutical companies to develop new customers and extend contracts for existing engagements.」

「The group regards the government’s promotion of generic drug use as an excellent opportunity and is pursuing synergies through group management, including by turning it into opportunities for BPO outsourcing contracts, such as staffing pharmaceutical manufacturers and medical institutions.」

「The group regards the government’s promotion of generic drug use as an excellent opportunity and is pursuing synergies through group management, including by turning it into opportunities for BPO outsourcing contracts, such as staffing pharmaceutical manufacturers and medical institutions.」

「The group is pursuing synergies through group management, including by turning government-mandated improvements in pharmaceutical distribution and the promotion of generic drug use into opportunities for BPO outsourcing contracts, such as staffing pharmaceutical manufacturers.」

「The group is pursuing synergies through group management, including by turning opportunities such as staffing pharmaceutical manufacturers into opportunities for BPO outsourcing contracts.」

「The group will seek to strengthen its relationships with pharmaceutical companies by leveraging the quality and scale of its group.」